VERNON HILLS, Ill., Aug. 3, 2017 /PRNewswire/ --áNexus Pharmaceuticals announced today that it has received approval
Isoproterenol Hydrochloride Injection USP is indicated for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy, for serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation), for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available, for bronchospasm occurring during anesthesia and as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock.
About Nexus Pharmaceuticals Inc.
Nexus Pharmaceuticals (www.nexuspharma.net) is a U.S. based healthcare company that specializes in developing and marketing generic sterile injectable products. Through our high quality generic products, Nexus Pharmaceuticals is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. The company's headquarters is in Vernon Hills, Illinois.
Isuprel« is a registered trademark of Hospira Inc.
Media Contact Nexus Pharmaceuticals Inc. Ayesha Ahmed847email@example.com
View original content:http://www.prnewswire.com/news-releases/nexus-pharmaceuticals-receives-fda-approval-for-isoproterenol-hydrochloride-injection-usp-300499307.html
SOURCE Nexus Pharmaceuticals Inc.
Subscribe to our Free Newsletters!
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...
It is time to enjoy the cool weather with the advent of the rains. Along with fun, one should also ...
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...View All